June 25, 2018
Exosome Diagnostics, Inc.
Bio-Techne To Acquire Exosome Diagnostics, Inc.
MINNEAPOLIS and WALTHAM, Mass., June 25, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced today that it has reached agreement to acquire Exosome Diagnostics, Inc. for $250 millionin cash plus contingent consideration of up to $325 million due upon the achievement of certain future milestones.
February 12, 2018
Phase 2 Influenza Vaccine Shows Broad Cross-Protection and Superiority in Nonclinical Study
FORT COLLINS, Colorado – February 12, 2018 − Vivaldi Biosciences, based at the Research Innovation Center at Colorado State University and Vienna, Austria, today announced that its deltaFLU influenza vaccine shows broad cross-protection against distantly related influenza strains, and superior protection versus a leading licensed vaccine in a recently completed nonclinical study.
November 28, 2016
Edwards Enters Into Agreement To Acquire Valtech Cardio
The purchase price of Valtech is $340 million in stock and cash at closing, with the potential for up to $350 million in additional pre-specified milestone-driven payments over the next 10 years. Prior to the close of the transaction, which remains subject to customary closing conditions and is expected in early 2017, Valtech will spin off its early-stage transseptal mitral valve replacement technology program. Edwards will retain an option to acquire that program and its associated intellectual property.